Get to know our clinical trials

Phase II/III, multicenter, randomized, double-blind clinical trial of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for the first-line treatment of PD-L1-positive squamous cell carcinoma of the head and neck.

Imagen Dr. Jose Maria Lopez-Picazo Gonzalez, Departamento de Oncologia Medica.
Dr. José Mª López-Picazo Curriculum
Specialist Medical Oncology Department
Navarre headquarters
Cancer Center
Head and Neck Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid

Technical Summary

  • PHASE II/III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF FICERAFUSP ALFA (BCA101) OR PLACEBO IN COMBINATION WITH PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF PD-L1-POSITIVE RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA.
  • Code EudraCT: 2024-519654-37
  • Protocol number: BCA101X301
  • Promoter: Biofabri
  • Molecule/Drug: BCA101
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION